Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 50

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 50
---
 Veracyte Diagnostics Platform will expand our ability to serve patients across the cancer care continuum.                                                                                                  |

#### 2024 Compensation Highlights
• Annual Cash Incentive Compensation Tied to Financial Performance. In 2024, our annual incentive award plan was designed to drive performance on key financial metrics — revenue and cash flow from operations. These metrics were achieved at 150%.

• Equity Mix. In 2024, our NEOs were granted a mix of PSUs and RSUs, with the equity mix consisting of 50% PSUs (at target) and 50% RSUs.

### Pay Program Overview
We believe that the design and structure of our pay program, and, in particular our incentive plans, support our business strategy and organizational objectives while successfully aligning executive focus and interest with that of stockholders. Our compensation programs are designed to reward our executives for superior short- and long- term performance. All pay elements, and the safeguards and governance features of the program, have been carefully chosen and implemented to align with our pay philosophy and objectives.

#### Veracyte2025 Proxy Statement47

#### Executive Compensation
In doing so, our Compensation Committee uses the following framework to achieve these objectives:

#### 2024 Target Pay Mix
Consistent with our philosophy of aligning executive pay with Veracyte’s short- and long-term performance, and to align the interests of management and stockholders, our compensation programs are designed such that the majority of executive compensation is in the form of variable , at-risk, incentive pay. For 2024, our Compensation Committee structured target pay packages for our Chief Executive Officer and NEOs was as follows:

#### 2024 CEO Pay Mix

#### 2024 Other NEO Pay Mix
Notes: Includes target annual cash-based incentives and the grant date fair value of annual equity grants, but excludes retention grants and new hire equity grants, which were not granted in 2024.

#### 48Veracyte2025 Proxy Statement

#### Executive Compensation

#### Compensation Governance
Our Compensation Committee is responsible for oversight of Veracyte’s compensation program and practices. The committee maintains a pay program defined by robust corporate governance and a commitment to stockholder interests. We have committed to numerous practices and safeguards to ensure the compensation program does not misalign those interests. These include:

| WHAT WE DO |     |                                                                                    |
|            |     | Pay-for-performance philosophy and culture                                         |
|            |     | An appropriate mix of short- and long-term incentives for our executives           |
|